Y-J. Ko

After Radiotherapy, Do Bone Metastases from Gastrointestinal Cancers Show Response Rates Similar to Those of Bone Metastases from Other Primary Cancers?

Amanda Hird, Edward Chow, Desmond Yip et al. · Current Oncology · 2008 · 46 citations · Full text

Medicine, Oncology, Radiation Oncology +17

LBA65 The Canadian Cancer Trials Group PA.7 trial: Results of a randomized phase II study of gemcitabine (GEM) and nab-paclitaxel (Nab-P) vs GEM, nab-P, durvalumab (D) and tremelimumab (T) as first line therapy in metastatic pancreatic ductal adenocarcinoma (mPDAC)

D. J. Renouf, Jennifer J. Knox, Petr Kavan et al. · Annals of Oncology · 2020 · 40 citations

Medicine, Oncology, Pharmacology +14

Results of a phase II study of single-agent nab-paclitaxel in platinum-refractory second-line metastatic urothelial carcinoma (UC).

Srikala S. Sridhar, Christina M. Canil, Som D. Mukherjee et al. · Journal of Clinical Oncology · 2011 · 14 citations

Medicine, Oncology, Pharmacology +16